TABLE 19.

Cannabinoids available by prescription in Canada

Agent	Trade name	Strengths available (mg)	Start dose (range)	Route of administration	Listed indications
Nabilone	Cesamet*	0.5, 1	0.5 mg/hs (1–2 mg bid)	Oral	Antiemetic in cancer chemotherapy
Synthetic Δ-9-THC	Marinol†	2.5, 5, 10	5 mg (5–10 mg bid)	Oral	Antiemetic in cancer chemotherapy
Extract of naturally occurring Δ-9-THC and CBD	Sativex‡§	2.7 Δ-9-THC/2.5 CBD**	–¶	Transbuccal	Adjunctive treatment for pain in multiple sclerosis

^*Valeant Canada Ltd;

^†Solvay Pharma Inc, Canada;

^‡GW Pharma Ltd, United Kingdom;

^§Approved under a conditional notice of compliance by Health Canada as of April 2005;

^¶Insufficient published information to make recommendations regarding dose at the time of writing;

^**Each spray contains 2.7 mg delta-9-tetrahydro-cannabinol (Δ-9-THC) and 2.5 mg cannabidiol (CBD). bid Twice a day; hs At bedtime